Making good on its threat, Eli Lilly has begun eliminating mandated price breaks to a few dozen hospitals that participate in a federal drug discount program after failing to receive comprehensive claims data. This decision marks a significant shift in Lilly’s approach to the 340B program, which is designed to provide discounted medications to safety-net hospitals serving low-income patients.
The move comes after the company warned earlier this month it would take such a step as part of a policy announced in January to reduce what it calls duplicate discounts paid to the hospitals. Trade groups representing hospitals, however, argue the move is unlawful and are calling for Congressional intervention. This conflict highlights the ongoing tension between pharmaceutical companies and healthcare providers regarding pricing transparency and compliance.
At the time, Lilly maintained that over 2,300 hospitals had complied with its demand, but some larger hospital systems across the U.S. refused to do so, despite recent follow-up letters regarding the policy that took effect on February 1. Up to 1,000 hospitals had not complied, prompting Lilly to press about 50 larger hospitals for the necessary data. This development could have broader implications for the 340B program and its beneficiaries, as compliance becomes increasingly scrutinized.
Open the full market picture for your next decision →
